The market for the treatment of Pompe disease will continue to expand as innovations enhance the treatment of patients and more treatments become accessible. Advancements in Enzyme Replacement Therapy ...

The US regulator has approved Nexviazyme (avalglucosidase alfa) for the treatment of patients aged one year of age and older with late-onset Pompe disease, which progressively attacks the heart ...

Living with Pompe disease and experiencing muscle weakness it will become known how much the weather and environment can affect your body. I used to get sick every winter because the freezing ...

Maze Therapeutics, Inc.’s MAZE share price has dipped by 5.71%, which has investors questioning if this is right time to buy.

Koeberl previously invented a gene therapy limited to treating late-onset Pompe disease that was licensed to AskBio. For nearly two decades, Dr. Koeberl has been working toward a treatment that ...

Case study 2: Fabry and Pompe disease treatment reimbursement in the Netherlands Fabry disease is estimated to affect 1 in every 40,000-120,000 people3, while Pompe affects 1 in 14,000-300,0004 ...

Pompe disease is a rare, hereditary disease caused by mutations in a gene called acid ... Their observations, combined with lab work results and the physical therapy evaluation, will help determine if ...

Katy Arvidson of Eagle River will compete this summer in the national pageant, which aims to reduce prejudice and ...